{"id":4390,"date":"2026-11-17T09:00:00","date_gmt":"2026-11-17T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4390"},"modified":"2026-11-18T21:45:30","modified_gmt":"2026-11-19T01:45:30","slug":"dual-tcr-editing-improves-engineered-t-cell-specificity","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4390","title":{"rendered":"Dual TCR Editing Improves Engineered T Cell Specificity"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Columbia_TCR_Editing_Technology_and_Modalities-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4413\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Columbia_TCR_Editing_Technology_and_Modalities-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Columbia_TCR_Editing_Technology_and_Modalities-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Columbia_TCR_Editing_Technology_and_Modalities-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Columbia_TCR_Editing_Technology_and_Modalities-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Columbia_TCR_Editing_Technology_and_Modalities.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Columbia University (academic)<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Peer-reviewed publication (JCI Insight, previously missed 17 Nov paper)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>CRISPR-Cas9 endogenous TCR deletion with transgenic TCR<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>TRAC\/TRBC1\/2 boundary-targeted editing<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>Endogenous TCR alpha and beta chains<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Melanoma (MART-1 model); autoimmunity models<\/p>\n<h4>Summary<\/h4>\n<p>An online-first peer-reviewed JCI Insight study published November 17 describes CRISPR removal of endogenous TCR-alpha and -beta chains while sparing introduced therapeutic TCR constructs. The authors report more than 90% receptor deletion in primary human T cells and improved antigen-specific function and tumor control in humanized mice.<\/p>\n<p>The Columbia-led group targeted intron\u2013exon boundaries of TRAC and TRBC1\/2 with Cas9 ribonucleoproteins, leaving intron-free transgenic TCRs intact. In a MART-1 TCR model, edited cells expressed more introduced receptor and enhanced in-vitro killing and mouse tumor control. Islet-reactive TCRs also showed stronger function for autoimmune modeling. This is an in-press, peer-reviewed preview; no patient was treated.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> broadly compatible endogenous-TCR deletion may reduce receptor mispairing and competition without redesigning every transgene, improving TCR therapy manufacturing.<\/p>\n<p><strong>Interpretation B:<\/strong> four cut sites plus lentiviral insertion may introduce rare chromosomal rearrangements, altered clones or immunogenicity not captured by targeted integration mapping and short mouse follow-up. Lack of observed GVHD in small humanized cohorts does not establish human safety. HLA restriction, antigen escape, tissue infiltration, T-cell exhaustion, dose\/persistence, scale-up and freedom to operate remain independent barriers. Comparing the platform with CAR-T requires tumor-specific and manufacturing endpoints, not receptor expression alone.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Engineered TCR T cells recognize peptide\u2013HLA complexes, including intracellular tumor antigens, but native alpha and beta chains can compete or mispair. CRISPR\u2013Cas9 makes targeted double-strand cuts to delete native receptor expression; the introduced receptor is retained.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Primary peer-reviewed preview verifies experimental claims.<\/li>\n<li>Missing: genome-wide rearrangement quantification, long-term clonal tracking, human safety, lot consistency and clinical efficacy.<\/li>\n<li>Upgrade: orthogonal genomic assays and GMP-scale replicates followed by controlled human data.<\/li>\n<li>Downgrade: rare rearrangements or inconsistent multi-locus editing.<\/li>\n<li>Falsifier: no durable functional gain versus a simpler single-edit workflow.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>This is a credible engineering advance for TCR cell therapy, with meaningful but entirely preclinical safety uncertainty.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: positive. Confidence in Facts: High. Confidence in Interpretation: Moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>An online-first peer-reviewed JCI Insight study published November 17 describes CRISPR removal of endogenous TCR-alpha and -beta chains while sparing introduced therapeutic TCR constructs. The authors report more than 90% receptor deletion in primary&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4413,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[1527,366,1528],"class_list":["post-4390","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-columbia-university","tag-crispr","tag-tcr-t-cells"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4390","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4390"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4390\/revisions"}],"predecessor-version":[{"id":4416,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4390\/revisions\/4416"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4413"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4390"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4390"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4390"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}